Keeping Up To Date on the Explosion of Cancer Immunotherapy
prIME Downloadable Slides
prIME Downloadable Slides

Keeping Up To Date on the Explosion of Cancer Immunotherapy

Not a member of My prIME? Join now for instant access.

Couldn’t make it to the Annual Meeting in Chicago? Download the meeting slides from top immunotherapy experts across various tumor types, including lung, head and neck, genitourinary, gastrointestinal, and breast cancer, presented at Keeping Up to Date With the Explosion of Immunotherapy in Cancer, our satellite symposium in collaboration with the Society for Immunotherapy of Cancer.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Jun 9, 2017

Expiration Date

Jun 9, 2018

Featured Expert

  • Mario Sznol, MD, Yale Cancer Center, New Haven, Connecticut, United States

Featured Topic

Immunotherapy in clinical practice: Lessons learned and unanswered questions

Featured Expert

  • Jean-Charles Soria, MD, PhD, Gustave Roussy, Villejuif, France

Featured Topic

Hot topic: Immunotherapy combinations

Featured Expert

  • Ramaswamy Govindan, MD, Washington University School of Medicine, Siteman Cancer Center, St Louis, Missouri, United States

Featured Topic

How is immunotherapy changing the face of cancer treatment—Lung cancer

Featured Expert

  • Tanguy Seiwert, MD, The University of Chicago Medicine, Chicago, Illinois, United States

Featured Topic

How is immunotherapy changing the face of cancer treatment—Head and neck cancer

Featured Expert

  • Brian I. Rini, MD, Cleveland Clinic, Cleveland, Ohio, United States

Featured Topic

How is immunotherapy changing the face of cancer treatment—Genitourinary cancers

Featured Expert

  • Michael A. Morse, MD, MHS, Duke University Medical Center, Durham, North Carolina, United States

Featured Topic

How is immunotherapy changing the face of cancer treatment—Gastrointestinal cancers

Featured Expert

  • Rita Nanda, MD, The University of Chicago Medicine, Chicago, Illinois, United States

Featured Topic

How is immunotherapy changing the face of cancer treatment—Breast cancer

Featured Expert

  • Brian I. Rini, MD, Cleveland Clinic, Cleveland, Ohio, United States

Featured Topic

prIME Points™

This educational activity is specifically designed to meet the needs of practicing medical oncologists, surgical and radiation oncologists, pathologists, and other healthcare professionals involved in the treatment of patients with cancer.

After successful completion of this educational activity, participants should be able to:

  • Identify patterns of response and specific adverse events associated with immunotherapies
  • Evaluate the evidence on the role of biomarkers for immunotherapies and their interpretation
  • Assess combination treatment strategies utilizing immunotherapy agents
  • Compare novel and emerging immunotherapies with established options for treatment

This educational activity is planned in collaboration with the Society for Immunotherapy of Cancer.

SITC Agenda Logo

This educational activity is supported by grants from Bristol-Myers Squibb and Merck & Co, Inc.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.